Targeted therapy: a new hope for thyroid carcinomas
Thyroid carcinomas are rare and heterogeneous diseases representing less than 1% of all malignancies. The majority of thyroid carcinomas are differentiated entities (papillary and folliculary carcinomas) and are characterized by good prognosis and good response to surgery and radioiodine therapy. Nevertheless, about 10% of differentiated carcinomas recur and become resistant to all therapies. Anaplastic and medullary cancers are rare subtypes of thyroid cancer not suitable for radioiodine therapy. A small percentage of differentiated and all the anaplastic and medullary thyroid carcinomas often recur after primary treatments and are no longer suitable for other therapies. In the last years, several advances have been made in the field of molecular biology and tumorigenesis mechanisms of thyroid carcinomas. Starting from these issues, the targeted therapy may be employed as a new option. The MAP-Kinase pathway has been found often dysregulated in thyroid carcinomas and several upstream signals have been recognized as responsible for this feature. RET/PTC mutations are often discovered both in papillary and in medullary carcinomas, while B-RAF mutation is typical of papillary and anaplastic histologies. Also mTOR disruptions and VEGFR pathway disruption are common features in all advanced thyroid cancers. Some angiogenesis inhibitors and a number of RET/PTC pathway blocking agents are yet present in the clinical armamentarium. Vandetanib, cabozatinib and sorafenib have reached clinical use. A number of other biological compounds have been tested in phase II and III trials. Understanding the biology of thyroid cancers may help us to design a well shaped targeted therapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Critical reviews in oncology, hematology - 94(2015), 1, Seite 55-63 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perri, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.critrevonc.2014.10.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956866337 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956866337 | ||
| 003 | DE-627 | ||
| 005 | 20230714142100.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2014.10.012 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956866337 | ||
| 035 | |a (DE-599)GBVOLC1956866337 | ||
| 035 | |a (PRQ)c1085-c06a5cc13bb18d3dc1512ca9082e1588744f4fe1621a1ac908bd14e27c6ae2500 | ||
| 035 | |a (KEY)0133835820150000094000100055targetedtherapyanewhopeforthyroidcarcinomas | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 1 | |a Perri, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted therapy: a new hope for thyroid carcinomas |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Thyroid carcinomas are rare and heterogeneous diseases representing less than 1% of all malignancies. The majority of thyroid carcinomas are differentiated entities (papillary and folliculary carcinomas) and are characterized by good prognosis and good response to surgery and radioiodine therapy. Nevertheless, about 10% of differentiated carcinomas recur and become resistant to all therapies. Anaplastic and medullary cancers are rare subtypes of thyroid cancer not suitable for radioiodine therapy. A small percentage of differentiated and all the anaplastic and medullary thyroid carcinomas often recur after primary treatments and are no longer suitable for other therapies. In the last years, several advances have been made in the field of molecular biology and tumorigenesis mechanisms of thyroid carcinomas. Starting from these issues, the targeted therapy may be employed as a new option. The MAP-Kinase pathway has been found often dysregulated in thyroid carcinomas and several upstream signals have been recognized as responsible for this feature. RET/PTC mutations are often discovered both in papillary and in medullary carcinomas, while B-RAF mutation is typical of papillary and anaplastic histologies. Also mTOR disruptions and VEGFR pathway disruption are common features in all advanced thyroid cancers. Some angiogenesis inhibitors and a number of RET/PTC pathway blocking agents are yet present in the clinical armamentarium. Vandetanib, cabozatinib and sorafenib have reached clinical use. A number of other biological compounds have been tested in phase II and III trials. Understanding the biology of thyroid cancers may help us to design a well shaped targeted therapy. | ||
| 540 | |a Nutzungsrecht: Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. | ||
| 650 | 4 | |a Carcinoma - genetics | |
| 650 | 4 | |a Thyroid Neoplasms - metabolism | |
| 650 | 4 | |a Carcinoma - therapy | |
| 650 | 4 | |a Carcinoma - pathology | |
| 650 | 4 | |a Thyroid Neoplasms - therapy | |
| 650 | 4 | |a Angiogenesis Inhibitors - therapeutic use | |
| 650 | 4 | |a Carcinoma - metabolism | |
| 650 | 4 | |a Proto-Oncogene Proteins c-ret - metabolism | |
| 650 | 4 | |a Proto-Oncogene Proteins B-raf - metabolism | |
| 650 | 4 | |a Thyroid Neoplasms - pathology | |
| 650 | 4 | |a Proto-Oncogene Proteins c-ret - genetics | |
| 650 | 4 | |a Proto-Oncogene Proteins c-ret - antagonists & inhibitors | |
| 650 | 4 | |a Protein Kinase Inhibitors - pharmacology | |
| 650 | 4 | |a Antineoplastic Agents - pharmacology | |
| 650 | 4 | |a Thyroid Neoplasms - genetics | |
| 650 | 4 | |a Angiogenesis Inhibitors - pharmacology | |
| 650 | 4 | |a Protein Kinase Inhibitors - therapeutic use | |
| 650 | 4 | |a Signal Transduction - drug effects | |
| 650 | 4 | |a Antineoplastic Agents - therapeutic use | |
| 650 | 4 | |a Proto-Oncogene Proteins B-raf - genetics | |
| 700 | 1 | |a Pezzullo, Luciano |4 oth | |
| 700 | 1 | |a Chiofalo, Maria Grazia |4 oth | |
| 700 | 1 | |a Lastoria, Secondo |4 oth | |
| 700 | 1 | |a Di Gennaro, Francesca |4 oth | |
| 700 | 1 | |a Scarpati, Giuseppina Della Vittoria |4 oth | |
| 700 | 1 | |a Caponigro, Francesco |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology, hematology |d Amsterdam : Elsevier, 1983 |g 94(2015), 1, Seite 55-63 |w (DE-627)167919229 |w (DE-600)605680-5 |w (DE-576)015904954 |x 0737-9587 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2015 |g number:1 |g pages:55-63 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.critrevonc.2014.10.012 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25465739 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2015 |e 1 |h 55-63 | ||